Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Google Disrupts Major Residential Proxy Network IPIDEA 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
The Maire - EuroChem Case: Three Lessons for Global Business 
NEW YORK, May 22, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the U.S. District Court for the Southern District of New York on behalf of investors who purchased Neurotrope, Inc. ("Neurotrope") (NASDAQ:NTRP) securities between January 7, 2016, and April 28, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/neurotrope-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the class period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
If you suffered a loss in Neurotrope you have until July 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/neurotrope-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
